FDAnews Drug Daily Bulletin
Pharmaceuticals / Research and Development

Celgene Discontinues Studies for Breast Cancer Treatment

Dec. 14, 2016
A A

Celgene will not proceed with a Phase 3 trial to evaluate Abraxane as a first-line treatment for breast cancer, following unfavorable Phase 2 results.

In the Phase II trial, 45 percent of patients who took Abraxane in combination with the chemotherapy carboplatin withdrew from the study. Another 25 percent of patients, who took Abraxane with the chemotherapy gemcitabine, discontinued the trial.

The company plans to redirect its cancer research efforts toward studies on the use of Abraxane in combination with immunotherapies.

View today's stories